Annals of Hematology

, Volume 97, Issue 10, pp 2001–2003 | Cite as

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine

  • Greta Scapinello
  • Marco Pizzi
  • Stefania Vio
  • Mitja Nabergoj
  • Andrea Visentin
  • Annalisa Martines
  • Laura Bonaldi
  • Livio Trentin
  • Gianpietro Semenzato
  • Francesco PiazzaEmail author
Letter to the Editor

Dear Editor,

Splenic marginal zone lymphoma (SMZL) is a low-grade B cell non-Hodgkin lymphoma (NHL) characterized by the involvement of the spleen, bone marrow, and peripheral blood [1, 2]. Cytogenetically, deletion or translocation of 7q32 is reported in 40% of patients, complete or partial trisomy of 3q in 30–80% and gain of 12q in 15–20% [3, 4, 5]. While a t(8;14) IGH/MYC may occur in the setting of transformation to a high-grade NHL [6], these alterations are extremely rare at diagnosis [7]. Also, a prolymphocytic evolution has been rarely recognized and it has been associated with a poor outcome [8]. We describe here a unique case of SMZL that displayed concurrently a t(8;14)(q24;q32) at diagnosis and a prolymphocytic evolution.

In a 51-year-old female admitted to the Padua University Hospital for recurrent bronchopneumonitis, a clonal B lymphocytosis of CD5 -small mature cells with compacted nuclear chromatin, moderately abundant slightly basophilic cytoplasm and typical membrane...



splenic marginal zone lymphoma


non-Hodgkin lymphoma


cluster of differentiation


myelocytomatosis mutated


lactate dehydrogenase



We are grateful to the patient for the availability of the collection of the data; nurses and colleagues from the Division of Hematology at the Department of Medicine, Padua University Hospital (PUH). We thank Dr. E. Piva from the Clinical Pathology Division of the PUH for the precious collaboration in preparing the PB smears.

Author contributions

GrS, MN, AV, LT, GS, and FP collected clinical data, supervised the work, and wrote the paper. SV performed the radiological analysis. MP performed the histological analysis. LB and AM performed the cytogenetic analysis.

Funding information

This work was made possible in part by the AIRC grant IG 18387 to FP.

Compliance with ethical standards


The consent to publication of the material was previously obtained. The principles of the Declaration of Helsinki were followed. The Padua Region Ethic Committee approved the work (n. 4089/AO17). Data are available at the Department of Medicine, Padua University Hospital, Division of Hematology, Surgical Pathology, Radiology, and at the Istituto Oncologico Veneto (IOV), Division of Cytodiagnostics.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Arcaini L, Rossi D, Paulli M (2016) Splenic marginal zone lymphoma: from genetics to management. Blood 127(17):2072–2081CrossRefGoogle Scholar
  2. 2.
    Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390CrossRefGoogle Scholar
  3. 3.
    Andersen CL, Gruszka-Westwood A, Atkinson S, Matutes E, Catovsky D, Pedersen RK, Pedersen BB, Pulczynski S, Hokland P, Jacobsen E, Koch J (2005) Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet 156(2):122–128CrossRefGoogle Scholar
  4. 4.
    Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luno E, Wlodarska I, Verhoef G, Garcia-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Sole F (2010) Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the splenic B-cell lymphoma group. Blood 116(9):1479–1488CrossRefGoogle Scholar
  5. 5.
    Zinzani PL (2012) The many faces of marginal zone lymphoma. Hematol Am Soc Hematol Educ Program 2012:426–432Google Scholar
  6. 6.
    Piris MA, Onaindia A, Mollejo M (2017) Splenic marginal zone lymphoma. Best Pract Res Clin Haematol 30(1–2):56–64CrossRefGoogle Scholar
  7. 7.
    Sonu R, Gregg J, Chen M (2012) Splenic marginal zone lymphoma with t(8;14)(q24.1;q32)/MYC rearrangement. J Hematop (5):141–7CrossRefGoogle Scholar
  8. 8.
    Hoehn D, Miranda RN, Kanagal-Shamanna R, Lin P, Medeiros LJ (2012) Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Hum Pathol 43(11):1828–1838CrossRefGoogle Scholar
  9. 9.
    Spina V, Rossi D (2017) Molecular pathogenesis of splenic and nodal marginal zone lymphoma. Best Pract Res Clin Haematol 30(1–2):5–12CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Greta Scapinello
    • 1
  • Marco Pizzi
    • 2
  • Stefania Vio
    • 3
  • Mitja Nabergoj
    • 1
    • 4
  • Andrea Visentin
    • 1
  • Annalisa Martines
    • 5
  • Laura Bonaldi
    • 5
  • Livio Trentin
    • 1
  • Gianpietro Semenzato
    • 1
    • 6
  • Francesco Piazza
    • 1
    • 6
    Email author
  1. 1.Hematology Unit, Department of Medicine - DIMEDUniversity of PadovaPadovaItaly
  2. 2.Surgical Pathology and Cytopathology Unit, Department of Medicine - DIMEDUniversity of PadovaPadovaItaly
  3. 3.Radiology Unit, Department of Medicine - DIMEDUniversity of PadovaPadovaItaly
  4. 4.Division of Hematology, Department of OncologyGeneva University HospitalsGenevaSwitzerland
  5. 5.Immunology and Molecular Oncology UnitVeneto Institute of Oncology, IOV-IRCCSPadovaItaly
  6. 6.Laboratory of Normal and Malignant HematopoiesisVenetian Institute of Molecular MedicinePadovaItaly

Personalised recommendations